Ocugen Secures $130M in Convertible Notes, Extending Cash Runway to 2028
Event summary
- Ocugen closed a $130M offering of 6.75% convertible senior notes due 2034, with net proceeds of ~$112.6M after expenses.
- The company used $32.7M of proceeds to fully repay its outstanding loan with Avenue Capital Group.
- Remaining proceeds will be used for general corporate purposes, including advancing three late-stage programs.
- Ocugen now expects its cash runway to extend into 2028, supporting its goal of filing three BLAs by 2028.
The big picture
Ocugen’s $130M convertible notes offering underscores the biotech’s strategic pivot to secure long-term financing amid a competitive gene therapy landscape. The move aligns with broader industry trends of companies extending cash runways to support late-stage pipeline advancements, particularly in high-risk, high-reward areas like retinal disease treatments. The debt repayment to Avenue Capital Group also signals a shift in capital structure, potentially reducing financial leverage while maintaining flexibility for future growth initiatives.
What we're watching
- Execution Risk
- Whether Ocugen can deliver on its goal of filing three BLAs by 2028, given the extended cash runway.
- Market Impact
- How the convertible notes offering will affect Ocugen’s stock price and investor sentiment.
- Pipeline Progress
- The pace at which Ocugen advances its late-stage programs for inherited retinal diseases and blindness diseases.
Related topics